Week In Review: EurekaBio Raises $40 Million To Support Lentiviral Vector Platform

Shenzhen EurekaBio closed a $40 Series B+ funding to support the commercialization of its EuLV Lentiviral Vector Production System, a technology that the company believes could transform large-scale production of lentiviral vectors.